EASL School: Alcohol-related liver disease: diagnosis, risk stratification and management
This EASL school is dedicated to chronic alcohol related liver disease, covering all aspects of the patient’s journey through the healthcare system. From alcohol’s impact on citizens in the society, to early disease detection, biomarkers used in healthcare pathways from primary to secondary care, global and specialised interventions, and new innovations to improve patient management. With the school, we aim to combat the stigma and taboo associated with the harmful effects of alcohol, and replace it with fully updated and high-quality evidence highlighting the many opportunities for improving our patient’s life and health.
The format of the school based on reversed-classroom format will be a platform for participants to discuss best-practice, gaps in knowledge, opportunities and barriers towards effective healthcare pathways. The topics will center around biomarkers and interventions: (1) existing and future diagnostic, monitoring and prognostic biomarkers, their applications, pitfalls and technical concepts. (2) existing and future interventions, whether pharmacological, psychosocial, or dietary, with a discussion of barriers and opportunities for giving patients’ access to effective treatments.
School Organisers: Prof. Aleksander Krag, Prof. Maja Thiele and Dr. Mads Israelsen
Learning objectives
- Understand the biases and stigma towards alcohol-related liver disease.
- Know how alcohol policies and average alcohol consumption influence a population’s risk of liver-related mortality.
- Know the principles, advantages and disadvantages of imaging and serum fibrosis markers in alcohol-related liver disease.
- Be familiar with the effects of pharmaceutical and psychosocial interventions to support alcohol rehabilitation.
- Discuss indications for invasive investigations such as a liver biopsy and liver vein catherisation in patients with alcohol-related liver disease.
- Critically appraise omics-based technologies as future diagnostic and prognostic tools in alcohol-related liver disease.
Target audience
- Hepatologists
- Clinical scientist (PhD fellows and post docs)
- Primary care doctors in training with special interest in alcohol-related harm
Top 3 reasons to attend
- To get updated on the management of ALD
- To discuss barriers and potential solutions for patients with ALD
- To increase your network of young investigators and experts in ALD
Add to your calendar
